These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 6734922

  • 1. Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
    Forconi S, Pieragalli D, Acciavatti A, Del Bigo C, Galigani C, Ralli L, Guerrini M, Di Perri T.
    J Int Med Res; 1984; 12(3):188-92. PubMed ID: 6734922
    [No Abstract] [Full Text] [Related]

  • 2. A placebo-controlled study of the effects of intravenous Buflomedil on foot skin microcirculation in patients with severe intermittent claudication.
    Van den Brande P, Maurel A.
    Angiology; 1998 Feb; 49(2):105-14. PubMed ID: 9482510
    [Abstract] [Full Text] [Related]

  • 3. Buflomedil in arterial occlusive disease: results of a controlled multicenter study.
    Trübestein G, Balzer K, Bisler H, Klüken N, Muller-Wiefel H, Unkel B, Mahfoud Y, Ziegler W.
    Angiology; 1984 Aug; 35(8):500-5. PubMed ID: 6383127
    [Abstract] [Full Text] [Related]

  • 4. [Buflomedil in arterial occlusive disease. Results of a controlled study].
    Trübestein G, Balzer K, Bisler H, Klüken N, Mahfoud Y, Müller-Wiefel H, Unkel B, Ziegler W.
    Dtsch Med Wochenschr; 1982 Dec 24; 107(51-52):1957-61. PubMed ID: 6756854
    [No Abstract] [Full Text] [Related]

  • 5. [Action and tolerability of delayed-action buflomedil in obliterating arteriopathies of the lower limbs. A multicenter study].
    Andreozzi GM, Lepore R.
    Clin Ter; 1990 Nov 30; 135(4):273-81. PubMed ID: 2150026
    [Abstract] [Full Text] [Related]

  • 6. Protective effects of buflomedil against exercise-induced reductions in regional erythrocyte deformability of patients with peripheral arterial disease.
    Guerrini M, Acciavatti A, Materazzi M, Rossi C, Del Bigo C, Forconi S, Di Perri T.
    J Int Med Res; 1982 Nov 30; 10(6):387-93. PubMed ID: 7152076
    [No Abstract] [Full Text] [Related]

  • 7. [Comparison of the effectiveness of intra-arterial and intravenous administration of buflomedil in patients with intermittent claudication].
    Diehm C, Eckstein M, Hübsch-Müller C.
    Vasa; 1989 Nov 30; 18(1):40-7. PubMed ID: 2648691
    [Abstract] [Full Text] [Related]

  • 8. Buflomedil for intermittent claudication.
    De Backer TL, Vander Stichele RH, Bogaert MG.
    Cochrane Database Syst Rev; 2001 Nov 30; (1):CD000988. PubMed ID: 11279700
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological preconditioning of ischaemia.
    Laghi Pasini F, Capecchi PL, Acciavatti A, Petri S, de Lalla A, Cati G, Colafati M, Di Perri T.
    Clin Hemorheol Microcirc; 1997 Nov 30; 17(1):73-84. PubMed ID: 9181761
    [Abstract] [Full Text] [Related]

  • 10. [Vascular and hemorheologic effects of buflomedil chlorhydrate in chronic obliterative arteriopathies of the legs].
    Coglitore S, Manganaro A, Barbera MC, Cento D, Buda D, Arrigo F, Consolo F.
    Minerva Cardioangiol; 1986 Nov 30; 34(11):745-9. PubMed ID: 2949163
    [No Abstract] [Full Text] [Related]

  • 11. Effects of buflomedil in a group of patients with chronic peripheral arterial diseases. Clinical and hemorheological evaluation.
    Mozzi E, Chiurazzi D, Spinola A, Annoni F, Germiniani R.
    J Int Med Res; 1985 Nov 30; 13(6):317-21. PubMed ID: 4076530
    [Abstract] [Full Text] [Related]

  • 12. A review of long-term safety data with buflomedil.
    Bachand RT, Dubourg AY.
    J Int Med Res; 1990 Nov 30; 18(3):245-52. PubMed ID: 2193838
    [Abstract] [Full Text] [Related]

  • 13. [Changes in systemic blood viscosity during induced intermittent claudication in peripheral obliterating arteriopathy].
    Forconi S, Guerrini M, Rossi C, Pecchi S, Di Perri T.
    Boll Soc Ital Cardiol; 1977 Nov 30; 22(4):441-6. PubMed ID: 617290
    [No Abstract] [Full Text] [Related]

  • 14. [Clinical experience and instrumental evaluation of buflomedil hydrochloride in the therapy of chronic obliterative arteriopathies of the legs].
    Lucisano V, Margheriti R, Matone P, Morrieri C, Rugolo A, Corsi V.
    Clin Ter; 1986 Jun 30; 117(6):499-509. PubMed ID: 3527536
    [No Abstract] [Full Text] [Related]

  • 15. Buflomedil for intermittent claudication.
    de Backer TL, Bogaert M, Vander Stichele R.
    Cochrane Database Syst Rev; 2007 Oct 17; (4):CD000988. PubMed ID: 17943749
    [Abstract] [Full Text] [Related]

  • 16. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.
    Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis SA.
    Int Angiol; 2001 Dec 17; 20(4):337-44. PubMed ID: 11782701
    [Abstract] [Full Text] [Related]

  • 17. [Effect of the vasoactive drug buflomedil in arterial occlusive disease].
    Racenberg J, Intaglietta M, Messmer K.
    Fortschr Med; 1982 Nov 04; 100(41):1926-30. PubMed ID: 7152426
    [Abstract] [Full Text] [Related]

  • 18. Experience with buflomedil in peripheral arterial occlusive disease.
    Balas P, Pagratis N.
    Angiology; 1981 Oct 04; 32(10):679-85. PubMed ID: 7325404
    [No Abstract] [Full Text] [Related]

  • 19. Buflomedil for intermittent claudication.
    de Backer TL, Bogaert M, Vander Stichele R.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD000988. PubMed ID: 18253982
    [Abstract] [Full Text] [Related]

  • 20. Buflomedil for intermittent claudication.
    de Backer TL, Vander Stichele R.
    Cochrane Database Syst Rev; 2013 Mar 28; 2013(3):CD000988. PubMed ID: 23543509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.